New drug combo shows promise for rare liver disease in early trial
NCT ID NCT06591455
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This early-phase study tested whether adding fenofibrate to standard treatment (ursodeoxycholic acid) helps people newly diagnosed with primary biliary cholangitis, a chronic liver disease. Thirty adults participated to see if the combination could normalize liver enzyme levels and reduce symptoms like itching and fatigue. The goal is better disease control, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xijing hospital
Xi'an, Shaanxi, 710032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common cholesterol drug help manage a rare liver disease?
- One pill may tame both itchy skin and stubborn liver disease
- Can a smartwatch help manage a rare liver disease? stanford study investigates
- Can breathing and meditation ease PBC symptoms? new study says maybe.
- New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
- 3000-Patient study aims to predict PBC outcomes from blood tests